パーキンソン病市場：KOLの洞察

当レポートでは、世界のパーキンソン病市場について調査し、市場の概要とともに、承認済み治療法、パイプライン動向、将来の見通しなどを提供しています。

目次

エグゼクティブサマリー

現在および将来の治療アルゴリズム

調査目的

パーキンソン病に対する現在の治療法

• 重要な洞察の概要

承認済み治療法

• ドーパミンアゴニスト
• 固定用量配合剤
• MAO-B阻害剤
• COMT阻害剤
• その他

パイプライン治療法

• ドーパミンアゴニスト
• 固定用量併用療法
• その他の作用機序
• 初期段階の薬剤候補
• その他の作用機序/パイプライン候補
• デジタルモニター/ウェアラブル

将来の治療パラダイム

• 重要な洞察の概要

付録

Where do KOLs see an opportunity for GSK's transdermal dopamine agonist ropinirole? How do KOLs assess the competing benefits of AbbVie's Duopa/Duodopa and levodopa/carbidopa fixed dose combinations? What challenges and benefits do experts see for AbbVie's ABBV-951 pipeline subcutaneous levodopa + carbidopa combination? Why do KOLs say disease modification by inhibiting alpha-synuclein remains a complex proposition? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (12)

Current and future treatment algorithm

Research objectives (3)

Current practice for treating Parkinson's disease (3)

• Key insights summary (3)
  • First-line treatment for PD is usually levodopa, a dopamine agonist or a MAO-B inhibitor, depending on symptom severity, age, health, concomitant diseases and patient formulation preference (1)

Approved therapies (69)

• Dopamine agonists (21)
  • Key insights summary (21)
• Fixed-dose combination agents (17)
  • Key insights summary (17)
• MAO-B inhibitors (12)
  • Key insights summary (12)
• COMT inhibitors (11)
  • Key insights summary (11)
• Other agents (8)
  • Key insights summary (8)

Pipeline therapies (133)

• Dopamine agonists (21)
  • LY03003 (rotigotine intramuscular injection; Luye Pharma Group) (8)
  • Aplindore (DAB 452; Seelos Therapeutics) (6)
  • Tavapadon (Cerevel Therapeutics) (7)
• Fixed-dose combination therapies (26)
  • Levodopa + carbidopa subcutaneous infusions (2)
  • ABBV-951 (Produodopa; foslevodopa + foscarbidopa subcutaneous infusion; AbbVie) (8)
  • ND0612 (levodopa + carbidopa subcutaneous infusion; NeuroDerm/Mitsubishi Tanabe Pharma) (4)
  • IPX203 (levodopa + carbidopa extended-release; Amneal Pharmaceuticals) (5)
  • P2B001 (pramipexole + rasagiline; Pharma Two B) (7)
• Other modes of action (33)
  • Levodopa Cyclops dry powder inhaler (PureIMS) (8)
  • DNL151 (Denali Therapeutics/Biogen) (6)
  • Nabilone FDT (AOP Orphan Pharmaceuticals) (6)
  • Mesdopetam (Integrative Research Laboratories) (7)
  • Buntanetap (R-phenserine; Posiphen; Annovis Bio) (6)
• Early-phase drug candidates (38)
  • Alpha-synuclein inhibitors (2)
  • UCB0599 (UCB) (1)
  • PRX002 (prasinezumab; Roche) (1)
  • ENT-01 (kenterin; Enterin) (1)
  • ION464 (Ionis Pharma/Biogen) (6)
  • Repurposed drugs (2)
  • Tasigna (nilotinib; Novartis) (8)
  • Cell transplantation therapies (2)
  • Cell therapies (GRF6021 [Alkahest/Grifols], NeurotrophinCell [Living Cell Technologies]) (7)
  • Viral gene delivery approaches (8)
• Other mechanisms of action/pipeline candidates (8)
  • Key insights summary (8)
• Digital monitors/wearables (7)
  • Key insights summary (7)

Future treatment paradigm (7)

• Key insights summary (7)
  • With disease modification a slim prospect in the next five years, the focus may remain on better management of fluctuations, dyskinesia and other pressing needs like frozen gait or dementia (5)

Appendix (4)

• KOL details (4)
  • KOLs from North America (1)
  • KOLs from Europe (2)